Evy Reviers is the daughter of a patient living with Amyotrophic Lateral Sclerosis (ALS).
As Chief Executive Officer of ALS Liga Belgium since 2006, Evy Reviers performs the general management of the organisation and coordinates the support to Belgian ALS patients. She has obtained several priority procedures to increase the quality of life of ALS patients in Belgium. At the European level, she is the Chairwoman of EUpALS, the European Organisation for Professionals and Patients with ALS, and defends the rights of ALS patients in scientific advice procedures at EMA. She is also a member of the ALS Dream Team, the Rare Diseases Organisation Belgium, the Drug Information Association, and EURORDIS. Between 2010 and 2016, she was a member of the Board of Directors of the International Alliance of ALS/MND Associations. She is member of the Executive Board of TRICALS.
Connect
Connect trials
PHOENIX trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
ADORE Trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
COURAGE-ALS Trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
APL2-ALS-206 Trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
TUDCA-ALS
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.